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CYP is a heme-containing enzyme present in liver, widely distributed from 
bacteria to mammals, and comprises a superfamily of metabolic enzymes that 
play an important role in the metabolism of endogenous substrates, 
environmental toxins, carcinogenic substances and a variety of 
pharmaceuticals.  
CYP2C19 is one of the most important members of these enzymes. Genetic 
polymorphism of CYP2C19 can lead to sever toxicity or therapeutic failure of 
medications as well as to a possible increase in an individuals susceptibility to 
certain types of chemically induced cancers and other diseases.  The aims of 
the present study was to determine the frequencies of CYP2C19*1, CYP2C19*2 
and CYP2C19*3 alleles and the associated CYP2C19 genotypes in Gaza Strip 
population. The study was conducted on 200 unrelated healthy human 
volunteers. DNA was extracted from blood samples and analyzed by the PCR-
RFLP method. The PCR product was digested with restriction enzymes (SmaI 
and BamHl) and then separated electrophoretically using 3% agarose gel. 
The frequencies of the CYP2C19*1, *2 and *3 alleles were 91.3, 5.8 and 3.0%, 
respectively. The distributions of CYP2C19*1/*1,*1/*2, *1/*3, *2/*2, *2/*3 and 
*3/*3 genotypes were 86.5, 6.5, 3.0, 1.5, 2.0, and 0.5 %, respectively. The 
distribution of CYP2C19*2 in the Gaza Strip population is lower than that in 
Caucasians, Africans and the Asian populations. The CYP2C19*1 however, is 
significantly higher in Gaza Strip when compared with other populations. The 
CYP2C19*3 allele, which was not reported in the Caucasian populations has 
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Cytochrome P450 (CYP) is a heme-containing enzyme widely distributed from 
bacteria to mammals, comprises a superfamily of metabolic enzymes that play 
an important role in the metabolism of endogenous substrates, environmental 
toxins, carcinogenic substances and a variety of pharmaceuticals. These 
enzymes oxidize a wide range of endogenous as well as exogenous 
compounds using atmospheric oxygen through a process called 'oxidative 
metabolism' [1].    
 
Mammalian CYP present in liver microsomes is characteristic of its nature in 
metabolizing exogenous compounds including drugs, pesticides, environmental 
pollutants, and carcinogens. Mammals contain at least 17 distinct CYP gene 
families that together code for an estimated 50-60 individual CYP genes in any 
given species [2].    
 
Genetic polymorphism of CYPs can lead to severe toxicity or therapeutic failure 
of medications as well as to a possible increase in an individuals susceptibility 
to certain types of chemically induced cancers and other diseases [1].     
 
1.2. Scope 
The polymorphic expression of cytochrome P4502C19 (CYP2C19) is known to 
be one of the determinants responsible for the pronounced interethnic and inter-
individual differences in response and disposition of clinically important drugs 
such as (S)-mephenytoin, diazepam, omeprazole, proguanil, citalopram, R-
warfarin and many antidepressants [3].  On the basis of their ability to 
metabolize (S)-mephenytoin or other CYP2C19 substrates, individuals can be 
classified as extensive metabolizers (EMs) or poor metabolizers (PMs). Carriers 
of two CYP2C19 nonfunctional alleles have a severely impaired capacity to 
 
metabolize drugs that are substrates for this enzyme and are hence designated 
poor metabolizers (PMs).  
 
Sixteen variant alleles (CYP2C19*2 to CYP2C19*16) that predict PMs have 
been identified. Among these variants, two alleles with separate mutations have 
been associated with the defective enzyme in Caucasian and Asian 
populations.  
 
The first is CYP2C19*2, which has a mutation in exon 5 causing an aberrant 
splice site. The other variant allele is CYP2C19*3 with a point mutation in exon 
4 producing a premature stop codon. The most commonly mutated allele is 
CYP2C19*2 in both Asians and Caucasian PMs. The second discovered 
mutation, CYP2C19*3, is rare among Caucasian subjects but accounts for the 
remaining defective alleles in Asian subjects [4].   
 
1.3. Justification of the study 
The medical practice today focuses mostly on the treatment after the disease 
onset while the molecular medicine promises the prevention before the 
disease onset. Now the genes responsible for diseases are being mapped on 
chromosomes and mutations precipitating the clinical conditions are being 
identified. The identification of susceptible populations through knowledge of 
their alleles could lead to the elucidation of mechanisms of disease and help to 
design the preventive strategies that are of the greatest benefit. 
 
1.4. Objective 
The main objective of this study is to determine for the first time the common 
CYP2C19 alleles in the Gaza strip population, and to compare them with the 
frequencies in other ethnic populations. 
 
1.5. Importance of the study 
Serious attention to inter-ethnic differences in drug response, started with the 
rise of pharmacogenetics. Therefore, genotype analysis before drug therapy 
 
seems to be a promising approach to reduce adverse effects and to enhance 
efficacy of drugs.  
 
It is hoped that our results may help in better understanding the molecular basis 
underlying ethnic differences in drug response, and contribute to improved 
individualization of drug therapy in the Palestinian population. This may reduce 
the risk of developing toxicity-related side effects to drugs which are 































2.1. Cytochrome P450  
The human genome encodes fifty-seven cytochrome P450 (P450, or CYP) 
proteins (Table 2.1). The majority of these are involved in the metabolism of 
steroids, bile acids, fatty acids, eicosanoids, and fat-soluble vitamins. Nearly 
fifteen P450s are involved in the metabolism of drugs and other xenobiotic 
chemicals and have received the most attention from pharmacologists. Many 
issues exist as to how to most logically deal with the major human P450s in the 
context of the drug development process. Many of these same xenobiotic 
metabolizing P450s also activate carcinogens [5].  
 
Table 2.1.  Major CYP genes and their main functions.*  
 
CYP  Gene                       Main functions 
CYP1                Xenobiotic metabolism 
CYP2  Xenobiotic metabolism, Arachidonic acid metabolism 
CYP3                  Xenobiotic and steroid metabolism 
CYP4                 Arachidonic acid or fatty acid metabolism 
CYP5                 Thromboxane synthesis 
CYP7                   Cholesterol 7-hydroxylation 
CYP8                    Prostacyclin synthesis 
CYP11   
Cholesterol side-chain cleavage, Steroid 11-
hydroxylation, Aldosterone synthesis. 
CYP17  Steroid biosynthesis 17-alpha hydroxylase 
CYP19  Androgen aromatization 
 
CYP21  Steroid biosynthesis 
CYP24     Vitamin D degradation 
CYP26      Retinoic acid hydroxylation 
CYP27       Steroid 27-hydroxylation 
CYP46          Cholesterol 24-hydroxylation 
CYP51          Cholesterol biosynthesis 
* Compiled from Nelson,  (2003) [6]. 
 
 
The most important P450 isoenzyme is CYP3A4 (50% of the P450 metabolism) 
followed by CYP2D6 (20%), CYP2C9 and CYP2C19 (together 15%). The 
remaining is carried out by CYP2E1, CYP2A6 and CYP1A2.  
The genes for CYP2D6, CYP2C9, CYP2C19 and CYP2A6 are functionally 
polymorphic. Therefore approximately 40% of human P450 dependent drug 
metabolism is carried out by polymorphic enzymes [7]. 
 
Cytochrome P450 (CYP450), which belongs to a superfamily of enzymes  are 
found in all forms of living organism. They are membrane bound heme-thiolate 
proteins (Figure 2.1); their most conserved structural features are related to 
heme binding and common catalytic properties, the major feature being a 
completely conserved cysteine serving as fifth (axial) ligand to the heme iron 
[8]. 
Most of the CYP450s are localized on the cytosolic side of the smooth 









 Protein chain= blue 
                                    Protoporphyrin  = red                                           
                                    Iron (III)   = silver                                         
                                   Thiocamphor    = green 
 
Figure 2.1. Cytochrome P450 Protein structure [8]. 
 
2.1.1. History and background 
The first experimental evidence relating to cytochromes P450 was discovered in 
1955 by Axelrod and Brodie [9, 10], who identified an enzyme system in the 
endoplasmic reticulum of the liver which was able to oxidize xenobiotic 
compounds. In 1958 Garfinkel and Klingenberg [11, 12] detected a CO binding 
pigment in liver microsomes which had an absorption maximum at 450nm. This 
was demonstrated to be a hemoprotein of the b-type class in 1964 [13, 14] 
which was named cytochrome P450 after the strong feature in its absorption 
spectrum. Electron spin resonance spectroscopy suggested that P450 is a low 
spin ferric hemoprotein  with a thiol residue as an axial heme ligand. This lead 
 
to explanations for the unusual Soret peak position and its perturbation upon 
the binding of substrates and other chemicals in terms of charge transfer 
modulated by the Fe - S bond. Raman spectroscopy provided confirmation of 
the presence of a Fe - S bond and identified this as a covalently bonded 
cysteine residue [15]. In 1985 a full structure of CYP101, a bacterial P450 from 
Pseudomonas putida, was obtained [16]. Subsequently, crystal structures have 
been obtained for the other CYP enzymes.  
 
Cytochrome P450 was originally discovered in rat liver microsomes. 
Microsomes are turbid suspensions made by grinding up cells and isolating the 
membrane fraction that is still in suspension after the cell debris and 
mitochondria have been pellet.  These mixtures are very opaque to standard 
spectroscopy, because they scatter light so badly.  The only way to measure a 
spectrum on turbid samples like these was to make a special instrument with 
the light detector very close to the cuvette, and to use dual beams and do 
difference spectroscopy.  In this way all the interfering substances and the light 
scattering could be subtracted out.  With this setup, microsomes treated with 
dithionite (reduced microsomes) and with carbon monoxide gas added to one 
cuvette only give a very strong absorption band at 450 nm, thus P450 (P is for 
pigment).  This is called a reduced CO difference spectrum.  The CO binds 
tightly to the ferrous heme, giving a difference between the absorbance of the 
two cuvettes.  This spectrum was first observed in 1958 [6]. 
 
2.1.2. Nomenclature 
The completion of the draft sequence of the human genome revealed the 
presence of 57 active human CYP genes, which are divided into 18 families and 
43 subfamilies and 58 pseudogenes [17]. 
Since cytochrome P450s are highly polymorphic and there are a lot of novel 
SNPs discovered continuously, there is a need to gather all the information 
about the consequences of the different allelic variants, and also have a 
consensus nomenclature system that is accepted and used by everyone in this 
particular field. For this purpose, a Web page [18], has been developed and 
 
contains the latest updated knowledge about the allelic variants of CYP1, 
CYP2, CYP3, CYP4, CYP5 and CYP8 genes in human.  
The CYPs are classified according to their amino acid sequence homology. The 
CYP450 enzymes that share less than 40% in amino acid sequence similarity 
belong to different families and are designated by an Arabic number. Further 
on, gene families are subdivided into gene subfamilies when sharing over 55% 
amino acid similarity and are designated by a letter [19]. 
 
Cytochrome P450 gene nomenclature consists of: 
1) the italicized root "CYP" denoting cytochrome P450,  
2) an Arabic numeral representing the P450 family,  
3) a letter representing the P450 subfamily and  
4) an Arabic numeral representing the actual gene [19].  
For instance, CYP2C19 is P450 gene 19 belonging to the C subfamily of family 
2. 
 
2.1.3. Function of P450 enzymes 
The CYP450 is divided into two major groups depending on their substrates: 
CYP450s that are involved in the oxidative metabolism of endogenous 
substances such as steroids, fatty acids, and prostaglandins and those that are 
responsible for the metabolism of exogenous substances such as drugs, 
environmental pollutants and carcinogens. In contrast to the latter with wide 
substrate specificity and a relatively poor species structural conservation, 
CYP450s that are involved in the oxidative metabolism of endogenous 
substances have very high affinities for their substrates and are very well 
conserved within species. The cytochrome P450 enzymes in families 13 
mediate 7080% of all phase I-dependent metabolism of clinically used drugs. 
They are responsible for the biotransformation, detoxification and excretion of 
foreign chemicals (such as drugs), from the body after the desired effect has 
been reached in humans by converting them into more soluble products, which 
makes them easier to be excreted via urine or the bile. [9] 
 
 
One of P450 enzymes functions is the metabolism of xenobiotics. Many 
lipophilic compounds, including drugs and environmental pollutants are 
metabolized by P450 enzymes whose main role is to make these compounds 
more hydrophilic, thereby increasing their elimination from the body. This occurs 
via Phase I or functionalization reactions which involve the addition of a 
hydrophilic functional group, such as -OH, to lipophilic compounds, thereby 
increasing their water solubility and increasing their renal elimination [19]. 
 
2.1.4. Phase I and Phase II reactions 
The reactions catalyzed by xenobiotic-biotransforming enzymes are generally 
divided into two groups, called phase I and phase II (Table 2.2). Phase I 
reactions involve oxidation, hydrolysis and reduction. These reactions expose or 
introduce a functional group (-OH, -NH2, -SH or -COOH), and usually result in 
only a small increase in hydrophilicity. Phase II biotransformation reactions 
include glucuronidation, sulfation, acetylation, methylation, conjugation with 
glutathione (mercaptopuric acid synthesis), and conjugation with amino acids 
(such as glycine, taurine, and glutamic acid) [20]. 
 
Among the phase I biotransformation enzymes, the cytochrome P450 system 
ranks first in terms of catalytic versatility and the sheer number of xenobiotics it 
detoxifies or activates to reactive intermediates [20]. 
 
Phase I and Phase II enzymes do not act according to the highly specific "lock-
and-key" mode. Luckily for us, they are capable of entering into a wide variety 
of chemical reactions because they encounter an enormous range of natural 








Table 2.2. List of Phase I and Phase II reactions [20]. 










Dehydration Alcohol dehydrogenase 
dehydration of amines Monoaminoxidases 
Oxidation 
N-oxidation, S-oxidation Flavin monooxygenases 




Hydrolysis Hydrolysis of epoxides Epoxide hydrolases 
Oxidation of radicals Superoxide dismutases 
Others 
peroxidation glutathione peroxidases 




acetylation O-, N-acetyltransferases 








2.1.5. Oxidative drug metabolism 
The P450 system is located in the smooth endoplasmic reticulum of the cell and 
is particularly abundant in the liver. On homogenizing these tissues, the 
endoplasmic reticulum is disrupted to form small vesicles called microsomes. 
For this reason, metabolising enzymes of the endoplasmic reticulum are called 
microsomal enzymes. At the active site of cytochrome P450 is an iron atom 
which, when in the oxidized form (Fe3+), binds the substrate (Figure 2.2) step1. 
 
Reduction of the enzyme-substrate complex occurs, with an electron being 
transferred from NADPH via NADPH cytochrome P450 reductase (step 2) [21]. 
 
 
P450 +++= Cytochrome P450 with iron in oxidized state (Fe+++) 
P450++= Cytochrome P450 with iron in reduced state (Fe++) 
S= substrate (drug) 
E= electron 
 
Figure 2.2 The cytochrome P450 mono-oxygenase system [21]. 
 
This reduced (Fe2+) enzyme-substrate complex then binds molecular oxygen 
(step 3) and is then reduced further by a second electron (step 4 or step 4). 
The enzyme-substrate-oxygen complex splits into water, oxidized substrate and 
the oxidized form of the enzyme. Carbon monoxide, which binds with the 
reduced form of the cytochrome, inhibits oxidation and gives a complex with an 
absorption peak at 450 nm, the origin of the name of the enzyme [22]. 
 
2.1.6. P450 enzyme multiplicity and overlapping substrate 
specificity 
Overlapping substrate specificity is a key feature which makes P450 enzymes 
highly effective detoxifiers of foreign compounds. A single P450 enzyme can 
metabolize a number of structurally unrelated compounds while any one 
chemical can be metabolized by a number of different P450 enzymes. In 
summary, enzyme multiplicity and overlapping substrate specificity enable the 
P450 enzyme system to detoxify a large variety of xenobiotics [19]. 
 
2.1.7. Factors affecting P450 enzyme activity 
The metabolic activity of P450 proteins may be regulated at various levels 
(Table 2.3). 
  
Table 2.3. Possible mechanisms causing deficiency of drug-metabolizing 
enzymes [19]. 
 Deletion, insertion, or rearrangement mutation of 
gene I. DNA/ RNA level 
 
Defect in transcription, RNA processing, or RNA 
stability 
 Decreased intracellular concentration or absence 
of enzyme protein 
- Diminished rate or lack of synthesis 
- Accelerated degradation of labile enzyme 
variant 
II. At enzyme protein 
level 
 
Normal intracellular concentration of mutant 
enzyme protein 
Decreased affinity for substrates (increased Km) 
Decreased maximal velocity (decreased Vmax) 
Combination of both of above. 
III. At level of 
enzyme function 
 
Change in the stereo-selectivity of the reaction 
 
Deletions, insertion, or substitutions in the coding sequence of the gene may 
affect the amount of active enzyme present or enzyme function. Mutations in 
regulatory sequences, defects in transcription or RNA processing may result in 
variable amounts or quality of mRNA produced. In addition, mRNA stability may 
have an impact on the amount of enzyme produced. Finally, enzyme induction 
or inhibition may alter the V-max, thereby altering the enzyme's ability to 
metabolize substrates. 
 
2.2. CYP2C subfamily 
The CYP2C subfamily is the second most abundant CYP protein in the human 
liver, representing about 20% of the total P450 [23]. This subfamily consists of 
three active members in the human liver, namely CYP2C8, CYP2C9, and 
CYP2C19. Of these, CYP2C9 and CYP2C19 have been characterized to be 
polymorphically expressed  [24]. 
 
CYP2C8 has been thought not to play an important role in drug metabolism 
since it is expressed at very low levels in the human liver. Still, the new, very 
potent anti-cancer drugs, for example anastrozole, primidone is partly 
metabolised by CYP2C8 [25]. CYP2C8 also participates in the metabolism of 
the endogenic agents retinol and retinoic acid [26].  
 
CYP2C9 is the major CYP2C isoform in the human liver [24], and it has been 
shown to be genetically polymorphic with at least three different alleles that 
produce differently active protein. The functional consequences of these 
polymorphisms are not yet clear, although CYP2C9 has a major role in the 
metabolism of many clinically important, weakly acidic drugs, such as S-
warfarin [27], tolbutamide, phenytoin [28], sulphamethoxazole [29] and many of 
the non-steroidal anti-inflammatory compounds [30] as well as the new drug in 
this class, a cyclooxygenase-II selective inhibitor, celecoxib [31].  
 
With CYP2C19, the genetic polymorphism leads to the poor metabolizer (PM) 
phenotypes exhibiting less active or completely inactive S-mephenytoin 4-
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hydroxylase. This PM phenotype is produced by at least two major and several 
minor variant alleles of CYP2C19 [24] and, consequently, CYP2C19 substrates 
are not metabolized as expected [32]. This may lead to accumulation of the 
drug and to in vivo concentrations exceeding the therapeutic level and 
producing unexpected toxic effects.  
 
2.2.1. The CYP2C19 gene  
The CYP2C19 gene (described in Table 2.4)  is located on chromosome 10 and 
has a size of 90 kb with nine exons expressing 1475 b of mRNA, (Figure 2.3) 
[33].  
 
Figure 2.3. CYP2C19 Gene . 
 
Table 2.4. Description of the CYP2C19 gene [34]. 
 
Symbol CYP2C19 
Gene name Cytochrome p450, family 2, subfamily C, polypeptide 19 
Alternate Names 
cytochrome P450, subfamily IIC (mephenytoin 4-
hydroxylase), polypeptide 19; flavoprotein-linked 
monooxygenase; mephenytoin 4'-hydroxylase; 
microsomal monooxygenase; xenobiotic 
monooxygenase 
Location 10q24.1-q24.3 
Gene atlas name Xenobiotic monooxygenase 
Synonym symbol(s) CPC1, CYP2C, P450C2C, CPCJ 
DNA structure 90.21 kb, 9 Exons 
mRNA size 1475 b 
Protein size 55.9 kDa, 490 aa 
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The CYP2C19 gene encodes the enzyme mephenytoin 4-hydroxylase more 
commonly referred to as the CYP2C19 enzyme. This protein localizes to the 
endoplasmic reticulum and is known to metabolize many xenobiotics, including 
the anticonvulsive drug mephenytoin, omeprazole, diazepam and some 
barbiturates. Many other drugs are also metabolized by CYP2C19 [34]. 
 
2.2.2. History 
In 1987 by somatic cell hybridization and in situ hybridization Riddell and Spurr 
assigned a gene for the cytochrome P450 with mephenytoin 4-prime-
hydroxylase activity (CYP2C) to chromosome 10q24.1-q24.3. In 1989 Shephard 
isolated and sequenced a cDNA clone that codes for a novel member of the 
P450IIC subfamily in man. Studies of Wrighton  and Goldstein in 1993, and 
1994 had demonstrated a correlation between the levels of CYP2C19 protein 
and microsomal S-mephenytoin 4-prime-hydroxylase activity in human liver. 
The molecular defect in CYP2C19 responsible for the poor metabolizer (PM) 
phenotype was determined by Goldstein and de Morais in 1994 [24].  
 
2.2.3. CYP2C19 functions 
CYP2C19 is responsible for the metabolism of a number of therapeutic agents 
such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain 
barbiturates, diazepam, propranolol, citalopram and imipramine [3]. Drugs may 
be themselves substrates for CYP2C19 enzyme and/or may inhibit or induce 
the enzyme [4].  
 
CYP2C19 is described according to the catalytic activity (Figure 2.4) as 
Cytochrome P450 2C19 ((R)-limonene 6-monooxygenase), ((S)-limonene 6-
monooxygenase), and ((S) - limonene 7-monooxygenase) (CYP2C19) (P450-
11A) (Mephenytoin 4 - hydroxylase) (CYPIIC17) (P450-254C) [35]. 
 It should be noted that P450-254c was originally listed as a separate gene 
(CYP2C17). Re-sequencing demonstrated that it is not a separate gene but a 
chimera. The 5' portion corresponds to a partial CYP2C18 clone, and the 3' 
portion corresponds to a partial CYP2C19 clone [35]. 
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1. (+)-(R)-limonene + NADPH + O2 = (+)-Trans- carveol + NADP (+) + H2O. 
2. (-)-(S)-limonene + NADPH + O2 = (-)-Trans- carveol + NADP (+) + H2O. 
3. (-)-(S)-limonene + NADPH + O2 = (-)-perillyl alcohol + NADP (+) + H2O. 
  
Figure 2.4 Catalytic activity reactions.  
 
 
2.2.4. CYP2C19 polymorphism 
 
Although many cytochrome P450 proteins may be induced and/or inhibited by 
xenobiotics, the P450 enzyme CYP2C19, is regulated primarily at the genetic 
level. Most of the inter-individual and inter-ethnic variation in human CYP2C19 
activities can be accounted for by genetic polymorphisms. Consequently, 
populations can be divided phenotypically into poor metabolizers (PMs) and 
extensive metabolizers (EMs) with respect to CYP2C19 based on the ability to 
metabolize selective CYP2C19-substrate drugs such as mephenytoin [36]. 
Mephenytoin is an anticonvulsant drug which is given in a racemic mixture. The 
R-enantiomer is N-demethylated, while the S-enantiomer is rapidly 4-
hydroxylated. The CYP2C19 polymorphism was originally identified when inter-
individual differences were observed in the mephenytoin S/R ratio. This was 
eventually attributed to a difference in the 4- hydroxylation of S-mephenytoin 
which is mediated by CYP2C19 [37].  
 
PMs may suffer adverse effects when treated with a routine clinical dose of a 
drug inactivated by CYP2C19 or may not gain therapeutic benefit from pro-
drugs activated by CYP2C19. For example, the antimalarial drug proguanil is 
administered as the pro-drug and requires activation by CYP2C19. PMs were 
found to be totally lack the active metabolite cycloguanil in their plasma and are 
at risk for failed protection from plasmodium infection by proguanil. PM subjects 
may be unable to detoxify some xenobiotic compounds which may be 
carcinogenic [37].   
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2.2.5. Inter-ethnic differences in CYP2C19 activity 
CYP2C19 has been studied in populations of varying ethnic backgrounds.  
There are significant inter-ethnic differences in CYP2C19 activity. 
Approximately 1% to 5% of Caucasians are poor metabolizers of S-
mephenytoin [38]. In contrast, Asian populations exhibit PM frequencies 
between 15% and 23% [39,40]. The most common genotype is the CYP2C19*1 
variation, which has normal enzyme activity. Three other major genotypes are 
also frequently seen, these are the CYP2C19*2, CYP2C19*3 and CYP2C19*4 
genotypes all leading to loss of enzyme activity [41,44].  
 
2.2.6. CYP2C19 alleles 
 
The wild type allele of CYP2C19 which was reported by Romkes in 1991 [42] 
has been designated CYP2C19*1A. A second wild type allele was described by 
Richardson at 1995 [43], and has been designated CYP2C19*1B. More than 25 
variants of CYP2C19 are known (Table 2.5). The most important of these 
alleles are: CYP2C19*2 (681GA), CYP2C19*3 (636GA), and CYP2C19*4 
(1AG). The nucleotide changes in the CYP2C19*2, *3, and *4, lead to a 
splicing defect, stop codon, and GTG initiation codon, respectively, and 
therefore to proteins with no activity [44].    
  








In vivo In vitro 
Reference 
CYP2C19*1A None   Normal Normal [47] 
CYP2C19*1B 99C>T; 991A>G I331V Normal   [43] 
CYP2C19*1C 991A>G I331V Normal  [48] 
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CYP2C19*2A 681G>A splicing defect None   [44] 















































None  [41] 
*Modified from the Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee [46]. 
 
2.2.7. CYP2C19 genotype: CYP2C19*2 and CYP2C19*3 mutant 
alleles 
The CYP2C19 PM phenotype is inherited as an autosomal recessive trait [34]. 
CYP2C19 PM individuals are homozygous for two mutant alleles which result in 
no active protein being expressed, while CYP2C19 EM individuals are either 
homozygous or heterozygous for the CYP2C19*1 (wild-type) allele. Two 
CYP2C19 mutant alleles, which are responsible for the PM phenotype, have 
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been described [44,45]. Additional null mutant alleles, which are present at very 
low frequencies, have also been identified. 
CYP2C19*2 contains a G681A substitution in exon 5 of the CYP2C19 gene. 
This nucleotide substitution results in the creation of an aberrant splice site 
which shifts the reading frame of the mRNA and produces a premature stop 
codon 20 amino acids downstream of the mutation. The result is a truncated, 
non-functional 234 amino acid CYP2C19 protein which lacks the heme-binding 
region [44]. The CYP2C19*2 mutant allele accounts for 83% of Caucasian 
CYP2C19 PMs and 75% of Japanese CYP2C19 PM alleles [44]. This suggests 
that additional CYP2C19 null mutant alleles exist. 
 
A second CYP2C19 mutant allele, called CYP2CI9*3, contains a G636A 
substitution mutation in exon 4 of the CYP2C19 gene. This mutation creates a 
premature stop codon which results in the formation of a truncated and inactive 
protein [45]. Although CYP2C19*3 accounts for the remaining 25% of Japanese 
CYP2C19 PM alleles not accounted for by CP2C19*2, it has not been found in 
Caucasian populations [45]. This evidence suggests, that there exist additional 
CYP2C19 mutant alleles which account for the remaining 17% of Caucasian 
CYP2C19 PM alleles which are not explained by CYP2C19*2 or CYP2CI9*3. 
Presumably, some of these individuals can be explained by the identified 
CYP2C19 null mutant alleles [44].     
 
2.2.8. Genetic regulation of CYP2C19 
P450 enzymes have a variety of gene regulatory mechanisms. Many of these 
genes can be turned on or induced by a chemical signal. The steroid hormones 
are under strict endocrine control. Their levels are tightly regulated. One 
example is the induction of steroid biosynthetic P450s by adrenocorticotropic 
hormone ACTH. ACTH stimulates production of cyclic adenine monophosphate 
(cAMP) that presumably activates a protein kinase that phosphorylates some 





2.2.9. Clinical consequences of CYP2C19 polymorphism 
CYP2C19 is involved in the metabolism of a wide variety of drugs including 
diazepam [52], omeprazole [53, 54], hexobarbital [55] and proguanil [52] 
(Table 2.6). For example, significant inter-individual and inter-ethnic differences 
exist in the clearance of diazepam. CYP2C19 EM individuals exhibit diazepam 
plasma clearance twice than that of CYP2C19 PM individuals [53]. 
 
Table 2.6. Examples of drugs metabolized by CYP2C19 [56].  
Proton pump inhibitors Anti-epileptics Others 
Omeprazole Phenytoin Amitriptyline 
Lansoprazole Diazepam Clomipramine 
Pantoprazole Phenobarbitone Cyclophosphamide 
  Progestrone 
 
 
2.2.10. Effect of non-genetic factors on CYP2C19 
 
Non-genetic factors, such as concomitant use of certain drugs, may be 
responsible for altering CYP2C19 phenotype. Presence of CYP2C19 substrate 
drugs, such as omeprazole, may affect phenotyping results due to competitive 
inhibition of the CYP2C19 protein. In addition, certain disease states such as 
acute hepatitis and cirrhosis, have been reported to decrease CYP2C19 







2.3. Review of some studies  
 
As genetic polymorphism of CYP2C19 can lead to severe toxicity or therapeutic 
failure of medications as well as to a possible increase in an individuals 
susceptibility to certain types of chemically induced cancers and other diseases, 
and for its unequal distribution among people of different geographical origins, 
there were many studies to investigate the frequencies of CYP2C19*2 and 
CYP2C19*3 alleles in different populations. 
 
A study on the Egyptian population for determining the frequencies of CYP2C19 
was done on 247 unrelated Egyptian subjects by isolation of genomic DNA then 
they sent DNA samples to their  laboratory in Japan for genotyping assay which 
revealed that the frequencies of the wild type (CYP2C19*1) and the non-
functional (*2 and *3) alleles were 0.888, 0.110 and 0.002, respectively. 
CYP2C19*3, which is considered an Asian mutation, was detected in one 
subject (0.40%) who was heterozygous (*1/*3). Two subjects (0.80%) were 
homozygous for *2/*2, while no compound heterozygote (*2/*3) or homozygote 
for *3 were detected. By Comparing their data with that obtained in several 
Caucasian, African-American and Asian populations, they found that Egyptians 
resemble Caucasians with regard to allelic frequencies of the tested variants of 
CYP2C19 [58]. 
 
An evaluation of CYP2C19 activity and the frequency of CYP2C19 alleles were 
conducted on 140 Jewish Israeli subjects who received 100 mg racemic 
mephenytoin and collected urine for 8 hours. Urinary concentrations of 
mephenytoin enantiomers and 4'-hydroxymephenytoin were determined by gas-
liquid chromatography and HPLC, respectively. CYP2C19 activity was derived 
from urinary S/R-ratio and 8-hour urinary excretion of 4'-hydroxymephenytoin. 
Mutations were identified by polymerase chain reaction and enzyme digestion 
with SmaI (CYP2C19*2) and BamHI (CYP2C19*3). Deficient mephenytoin 
hydroxylation was found in 4 subjects (2.9%; 95% confidence interval [CI], 0.1% 
to 5.7%) who were homozygous for CYP2C19*2. CYP2C19*2 was the major 
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deactivating allele accounting for 15% (95% CI, 11% to 19%) of CYP2C19 
alleles, whereas CYP2C19*3 was identified in 2 subjects (1%; 95% CI, 0% to 
2%). Among 136 extensive metabolizers, 99 were homozygous for CYP2C19*1 
and 37 were compound heterozygous CYP2C19*1/CYP2C19*2 (35 subjects) or 
CYP2C19*1/CYP2C19*3 (2 subjects). They realized that the frequency of poor 
metabolizers of CYP2C19*2 and CYP2C19*3 allele in the Jewish Israeli 
population resembles findings in non-Asian populations. And they found 
complete concordance between phenotypic and genotypic findings [59]. 
 
In 1997 a study examined whether the genotype predicted the phenotype in 
Japanese, Filipino and Saudi Arabian populations, and compared the 
frequencies of the defective CYP2C19 alleles in these populations with those 
found in European-Americans, Chinese-Taiwanese, and African-Americans 
from North Carolina. Among 53 Japanese, 15% were PMs and among 52 
Filipinos 23% were PMs. Among 97 Saudi Arabians, only two were PMs. There 
was a complete concordance between genotype and phenotype in all three 
populations. The incidence of CYP2C19*2 was 0.23 (95% confidence limits 
0.15-0.31) in Japanese, 0.39 (95% confidence limits 0.29-0.48) in Filipinos, 0.32 
(95% confidence limits 0.26-0.38) in Chinese-Taiwanese, 0.15 (95% confidence 
limits 0.10-0.20) in Saudi Arabians, 0.13 (95% confidence limits 0.08-0.17) in 
European-Americans, and 0.25 in African-Americans from North Carolina (95% 
confidence limits (0.14-0.31). The incidence of CYP2C19*2 in Saudi Arabians 
was similar to that found in European-Americans, and significantly lower than 
that found in Oriental populations or African-Americans (p < 0.05). CYP2C19*3 
was not found in European-Americans, Saudi Arabians or African-Americans 
(95% confidence limits 0-0.014). The incidence of CYP2C19*3 in the three 
Oriental populations ranged from 0.10 (95% confidence limits 0.05-0.17) in 
Japanese and 0.08 (95% confidence limits 0.03-0.13) in Filipinos to 0.06 (95% 
confidence limits 0.03-0.08) in Chinese-Taiwanese [60].  
  
A new study was done in 2005 to establish the frequencies of CYP2C19*1, *2 
and *3 in the south Indian population and to compare them with the interracial 
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distribution of the CYP2C19 genetic polymorphisms. Genotyping analysis of 
CYP2C19 was conducted in unrelated, healthy volunteers from the three south 
Indian states of Andhra Pradesh, Karnataka and Kerala, by the PCR RFLP. 
CYP2C19*1, *2 and *3 frequencies were 0.64, 0.35 and 0.01, respectively. 
CYP2C19*2 was higher than in Chinese and Caucasians. The relatively high 
CYP2C19 poor-metabolizer genotype frequency of 12.6% indicates that over 
28 million south Indians are poor metabolizers of CYP2C19 substrates [61].  
 
The incidence of the S-mephenytoin polymorphism was compared in two 
Chinese ethnic groups, Han (n = 101) and Bai (n = 202) by phenotype and 
genotype analysis. The frequency of poor metabolizers (PMs) in Han vs. Bai 
subjects was 19.8% vs. 13.4%. Han subjects had a higher frequency of the 
mutant CYP2C19*2 allele (0.366 vs. 0.257, P < .01) and a lower frequency of 
the wild-type allele (0.559 vs. 0.688, P < .01) than Bai subjects, which was 
consistent with the difference in the frequencies of PMs between the two ethnic 
groups [62].  
 
The variant m1 allele (CYP2C19*2A) of the CYP2C19 gene was evaluated for 
its association with prostate cancer risk among a Swedish population, but no 
significant differences were found between cancer patients and controls [63]. A 
very small study on Japanese patients revealed a significant association of the 
poor metabolizers (PM) genotype with squamous cell carcinoma of the lung, but 
the association with bladder cancer seen in Caucasians was not found [64]. 
Moreover, CYP2C19 PM with HCV-seropositive subjects was found to be 
associated with a high risk for developing hepatocellular carcinoma (HCC) [65].  
 
In 2004 an investigation of the association between cytochrome P450 2C19 
(CYP2C19) gene polymorphism and cancer susceptibility by genotyping of 
CYP2C19 poor metabolizers (PMs) in cancer patients was done  in Chinese 
population. One hundred thirty five cases of esophagus cancer, 148 cases of 
stomach cancer, 212 cases of lung cancer, 112 cases of bladder cancer and 
372 controls were genotyped by allele specific amplification-polymerase chain 
reaction (ASA-PCR) for CYP2C19 PMs. The frequencies of PMs of CYP2C19 
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were 34.1% (46/135) in the group of esophagus cancer patients, 31.8% 
(47/148) in the stomach cancer patients, 34.4% (73/212) in the group of lung 
cancer patients, only 4.5% (5/112) in the bladder cancer patients and 14.0% 
(52/372) in control group. There were statistical differences between the cancer 
groups and control group. The study concluded that CYP2C19 PMs have a high 
incidence of esophagus cancer, stomach cancer and lung cancer, conversely 
they have a low incidence of bladder cancer. It suggests that CYP2C19 may 
participate in the activation of procarcinogen of esophagus cancer, stomach 
cancer and lung cancer, but may be involved in the detoxification of 
carcinogens of bladder cancer [66].  
 
A discordance of the cytochrome P4502C19 genotype and phenotype in 
patients with advanced cancer was concluded from the examination of the 
relationship between CYP2C19 genotype and expressed metabolic activity in 
16 patients with advanced metastatic cancer.  
Individual CYP2C19 genotypes were determined by PCR based 
amplification, followed by restriction fragment length analysis, and compared 
with observed CYP2C19 metabolic activity, as determined using the log 
hydroxylation index of omeprazole. All 16 patients had an extensive metabolizer 
genotype. However, based on the antimode in a distribution of log omeprazole 
hydroxylation indices from healthy volunteers, four of the patients had a poor 
metabolizer phenotype and there was a general shift of the remaining 12 
patients towards a slower metabolic phenotype. This suggests a reduction in 
metabolic activity for all patients relative to healthy volunteers. A careful 
analysis of patient medical records failed to reveal any drug interactions or other 
source for the observed discordance between genotype and phenotype. Such a 
decrease in enzyme activity could have an impact on the efficacy and toxicity of 
chemotherapeutic agents and other drugs, used in standard oncology practice 
[67].  
  
An evaluation for the efficacy of triple therapy with proton pump inhibitor (PPI)  
on eradication of Helicobacter pylori infection in relation to cytochrome P450 
 
2C19 (CYP2C19) and P-glycoprotein (MDR1) gene polymorphisms was done. 
The retrospective study involved 70 Polish Caucasian patients with H. pylori 
infection, diagnosed and treated with one of the two different triple therapy 
regimens [omeprazole, amoxicillin, and clarithromycin (OAC) or pantoprazole, 
amoxicillin, and metronidazole (PAM)]. Using genomic DNA, CYP2C19 (*2 and 
*3) and C3435T MDR1 alleles were determined by means of PCR-RFLP 
assays. A significantly higher prevalence (P<0.05) of heterozygous extensive 
metabolizers with CYP2C19*1/*2 genotype (32.4% versus 8.3%) and 
homozygous with 3435TT MDR1 genotype (38.2% versus 13.9%) was found in 
patients cured after the first cycle of triple therapy than in patients with failure of 
eradication after the first cycle. CYP2C19*1/*2 and 3435TT MDR1 genotypes 
as well as PAM regimen of treatment were also predictive of successful 
eradication of H. pylori infection after the first cycle of triple therapy at 
univariate/multivariate logistic regression analysis. This pharmacogenetic study 
on the influence of different CYP2C19 and C3435T MDR1 genotypes on H. 
pylori eradication suggests that CYP2C19 and MDR1 polymorphisms may be 
independent predictable determinants of the efficacy of triple therapy including 
PPI. The PAM regimen of treatment seems to be more effective after the first 
cycle of the therapy than the OAC regimen [68].  
 
In United States the researches suggested that treatment decisions for H. pylori 
infection that are based on a patient's CYP2C19 genotype decreases expenses 
for health plans implementing testing. This analysis provides an economic basis 
to support recent calls to expand this technology into routine clinical care to 
prevent toxicity of narrow therapeutic index drugs. As the clinical outcome of 
duodenal ulcer treated with proton pump inhibitor based, anti- H. pylori 
regimens varies according to cytochrome P450 2C19 genotype. CYP2C19 
genotypes differ markedly in peoples of Pacific Rim descent compared with 
another ethnicity. So authors sought to determine the specific impact that these 
factors have on the cost-effectiveness of duodenal ulcer management. Their 
model consisted of two patient cohorts with H. pylori and duodenal ulcer, 
trichotomized into CYP2C19 homozygous extensive metabolizers (EMs), 
 
heterozygous EMs, and poor metabolizers (PMs), altering the anti- H. pylori 
regimen in the genotyped cohort only. The authors took the perspective of a 
third-party payer, and the denominator was ulcer episode prevented. In the 
reference case, the use of CYP2C19 genotyping prior to initiating anti- H. pylori. 
therapy was dominant (costs were saved with each ulcer episode prevented) in 
all geographic regions of the United States. The subsequent break-even 
analysis showed a range of $89.20 to $118.96 - from Hawaii to the Midwest, 
respectively - required to eliminate the cost-savings from each genotype test 
performed. Using probabilities most unfavorable to genotyping, the variation of 
peoples with Pacific Rim origins from 0% to 100% altered the cost-effectiveness 
from $495 to $2125 per ulcer event prevented, respectively [69].  
 
Some CYP variants were associated with increased risks for cancers of the 
lung, esophagus, and head and neck. The overall effects of common CYP 
polymorphisms were found to be moderate in terms of penetrance and relative 
risk, with odds ratios ranging from 2 to 10. Tobacco use is causally associated 
with cancers of the lung, larynx, mouth, esophagus, kidneys, urinary tract, and 
possibly, breast. Major classes of carcinogens present in tobacco and tobacco 
smoke are converted into DNA-reactive metabolites by cytochrome P450 
(CYP)-related enzymes, several of which display genetic polymorphism. 
Individual susceptibility to cancer is likely to be modified by the genotype for 
enzymes involved in the activation or detoxification of carcinogens in tobacco 
and repair of DNA damage [70].  
 
A study was done to discover if there is an association between CYP2C19 
polymorphism and susceptibility to systemic lupus erythematosus (SLE). As the 
etiology of SLE is still unknown. In several cases, however, chemicals or drugs 
were identified as etiological agents and associations with certain phenotypes of 
drug metabolising enzymes have been reported. They use Racemic 
mephenytoin (100 mg orally) which was given to healthy volunteers (n=161) 
and SLE patients (n=37) and then S-mephenytoin and R-mephenytoin were 
determined in eight hour urine samples, blood samples were obtained for 
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genotypic assay, each blood sample was tested for the detection of CYP2C19*1 
and CYP2C19*2 by oligonucleotide ligation assay. The ratio of S/R-
mephenytoin ranged from <0.1 to 1.293 in healthy subjects and from <0.1 to 
1.067 in SLE patients. PM phenotype was observed in 2 of 37 patients with 
idiopathic SLE (5.4 %) and 6 of 161 healthy subjects (3.7 %). There were no 
significant differences in the frequency of PM phenotypes between the groups 
(Fisher's exact test, p= 0.64) or in the frequency distribution profiles of ratios of 
S-mephenytoin to R-mephenytoin. No significant differences in distribution of 
overall genotypes and in allele frequencies were observed between the two 
groups. No significant relation was found between clinical features and the 
overall genotype. From these results the authors concluded that CYP2C19 
genotype does not represent a genetic predisposition in idiopathic SLE patients 
[71].  
 
The aim of this study was to investigate the frequencies of most common allelic 











Materials and Methods 
 
3.1. Study population 
The present study was carried out on 200 unrelated healthy Palestinian subjects 
residing in Gaza Strip. They assumed to be healthy unrelated subjects from the 
Gaza diagnostic center, European Gaza hospital, and students of the Islamic 
University, the subjects were selected regardless of sex and age. An approval 




Chemicals and reagents used in this study are listed below (Tables 3.1 and 
3.2). All chemicals were of analytical and molecular biology grade. 
 
Table 3.1. Chemicals and reagents. 
Chemicals and reagents Supplier 
Wizard Genomic DNA Purification Kit Promega (Madison, USA) 
PCR Master mix Promega (USA) 
Agarose gel Promega (USA) 
Nuclease free water Promega (USA) 
SmaI Restriction enzyme New England Bio Labs (USA) 
50 bp DNA ladder New England Bio Labs (USA) 
Low molecular weight marker New England Bio Labs (USA) 
BamHl restriction enzyme Sigma diagnostics (USA) 
PCR primers Operon (Germany) 
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Table 3.2. Solutions and their contents.  
Solution Contents 
DNA gel loading buffer 
(Bromophenol blue) (6X) 
0.25% Bromophenol blue 
40% (w/v) sucrose in water 
DNA gel loading buffer (Orange G) 
(10X) 
0.2% Orange G 
40% (w/v) sucrose in water 
Tris  Acetate  EDTA (TAE) (50X) 
2M Tris base (pH 8), 1M Glacial acetic 
acid, 0.05M EDTA (pH 8) 
Ethidium Bromide (EtBr)  (10mg/ml) 
 
3.2.2. PCR primers 
All PCR primers are indicated from 5' to 3' end. Sense primers are marked with 
(F) while antisense primers are marked with (R). The primer sequences were 
obtained from published literature and are provided in Table 3.3. 
 
Table 3.3. PCR primers used in the study. 
Sequence Name Nucleotide Sequence Reference 
CYP2C19*2 (F) CAGAGCTTGGCATATTGTATC 
CYP2C19*2 (R) GTAAACACACAACTAGTCAATG 
[66] 
CYP2C19*3 (F) TGTTTCCAATCATTTAGCTTCACC 





The experimental part of the work was done in the Islamic university genetic 
lab. The important equipments that were used are listed in Table 3.4. 
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Table 3.4. List of major equipment. 
Instruments Manufacturer 
Thermocycler, mastercycler personal Eppendorf, Germany 
Electrophoresis chambers and 
Electrophoresis power supply 
Biorad, USA 
Microcentrifuge  Sanyo, U.K 
Hoefer MacroVue UVis-20 Hoefer, USA 
Microwave L.G, Korea 





3.3.1. DNA extraction 
3.3.1.1. Sample collection and preparation 
EDTA tubes were used for collection of blood. About 2.5 ml of venous blood 
were withdrawn into sterile EDTA tubes and mixed gently. The blood samples 
were then stored at -70°C until time of DNA extraction and purification.  
 
 
3.3.1.2. DNA extraction and purification 
Genomic DNA was isolated from blood using Wizard Genomic DNA Purification 
Kit (Promega, USA), the contents of which are given in Table 3.5, according to 






Table 3.5. Wizard genomic DNA purification kit solutions. 
Solutions volume 
cell lyses solution 100 ml 
nuclei lyses solution 50 ml 
protein precipitation solution 25 ml 
DNA rehydration solution 50 ml 
RNase solution  250 µl 
 
 
3.3.1.3. Isolation of genomic DNA 
Three hundred µl good mixed blood were added to 1.5 ml micro centrifuge tube 
containing 900 µl of cell lyses solution (lyses the red blood cells and white blood 
cells), mixed by inverting the tube gently and the mixture was incubated at room 
temperature for 10 minutes. During the incubation period the tube was 
periodically mixed (2-3 times) by inversion. 
 
The mixture was centrifuged at 13,000 rpm for 20 seconds, then the 
supernatant was removed and discarded without disrupting the visible white 
pellet, after that the white pellet was resuspended by vigorous vortexing (10-15 
seconds). 
 
Three hundred µl nuclei lyses solution (lyses the nuclear membrane of white 
blood cells nuclei) were added to the resuspend pellet with pipeting the solution 
5-6 times. The solution should become very viscous; the samples with visible 
clumps should be incubated at 37oC until the clumps are disrupted. 
 
One and a half µl RNase solution (digests the RNA) was added to the nuclear 
lysate and they were mixed by inverting 2-5 times, then incubated at 37oC for 
15 minutes, and the mixture was cooled to room temperature. 
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One hundred µl protein precipitation solutions (precipitates all the cellular and 
nuclear proteins) were added to the cooled nuclear lysate and they were mixed 
vigorously for 10-20 seconds by the vortex -Small protein clumps may be visible 
after vortexing- then centrifuged at 13000 rpm for 3 minutes. A dark brown 
protein pellet should be visible. 
 
The supernatant was then transferred to a clean 1.5 ml micro centrifuge tube 
containing 300 µl isopropanol and was mixed gently by inversion until white 
thread-like strands of DNA form a visible mass, then centrifuged at 13000 rpm 
for 1 minute. The DNA will be visible as a small white pellet. 
 
The supernatant was removed and 300µl of 70% ethanol were added to the 
small white pellet and gently inverted several times to wash the DNA pellet, 
then centrifuged at 13000 rpm for 1 minute. 
 
The ethanol was aspirated carefully using a micropipette, and then the tube was 
inverted on a clean absorbent paper. The pellet was air-dried for 10-15 minutes. 
 
The DNA pellet was rehydrated by addition of 100µl DNA rehydration solution 
and incubation at 65oC for 1 hour. The DNA pellet should be mixed periodically 
by gently tapping the tube. 
  
Finally The DNA was stored at 2-8oC until PCR analysis. 
 
3.3.2. PCR procedure 
The two most common allelic variants (CYP2C19*2 and CYP2C19*3) of 
CYP2C19 were investigated using PCR followed by restriction analysis i.e., 
PCR-RFLP. 
 
For CYP2C19*2 detection (Figure 3.1), a segment of exon 5 which contains the 
base pair substitution 681G>A  was amplified using the primer set presented in 
 
Table 3.3 and the PCR product (168bp) was restricted using  SmaI restriction 
enzyme which cuts the normal allele into two segments (118 bp and 50 bp) but 
doesn't cut  the abnormal allele. The CYP2C19*2 homozygotes should yield 
one band (168 bp) while the CYP2C19*2 heterozygotes should produce three 
bands (168 bp, 118 bp, and 50 bp). Homozygotes for the normal allele should 
give two bands (118 bp and 50 bp). 
 
For CYP2C19*3 detection, a segment of exon 4 which contains the base pair 
substitution 636G>A  was amplified using the primer set presented in Table 3.3 
and the PCR product was restricted using BamHl restriction enzyme which cuts 
the normal allele into two segments (175 bp and 96 bp) but doesn't cut  the 
abnormal allele. The CYP2C19*3 homozygote should yield one band (271 bp) 
while the CYP2C19*3 heterozygotes should produce three bands (271 bp, 175 
bp, and 96 bp). Homozygotes for the normal allele should give two bands (175 
bp and 96 bp). 
 
The amplicons of CYP2C19*2 and CYP2C19*3 were prepared separately using 
a PCR master mix (Promega), Table 3.6, and appropriate primer sets at a 
concentration of 0.4ìM each. The quantity of the DNA used were determined 
using the spectrophotometer at 260 nm wavelength (1.0 absorbance = 50 
µg/ml). The concentrations and volumes of the PCR mix are presented in Table 
3.7. The negative controls (with no DNA template) were applied with each PCR 
run.     
 
Table 3.6. PCR master mix buffers and solutions. 
Concentration Solution 
50 units/ml Taq DNA Polymerase [supplied in a proprietary reaction buffer (pH 8.5)] 
400 µM Each: dATP, dGTP, dCTP, dTTP 
3 mM MgCl2 
 
Table.3.7. The concentrations and volumes of the PCR mix for 25 µl reaction 
volume.                                                                                                                                                                                                                                                                                
Component Volume Final Concentration 
PCR master mix, 2x 12.5 µl 1x 
Forward primer (10µM) 1 µl 0.4 µM 
Reverse primer (10µM) 1 µl 0.4 µM 
DNA template 4 µl ≈ 200 ng 
Nuclease free water  6.5 µl  
 
3.3.2.1. CYP2C19*2 PCR-RFLP procedure 
The PCR mix was amplified as follows: pre-heating (40 oC, 2 min), and initial 
denaturation (95 oC, 3.0 min) were followed by 35 cycles of denaturation  (95 
oC, 1 min), annealing (53 oC, 1.0 min), and extension (72 oC, 1.5 min) followed 
by a final extension step (72 oC, 10 min).  
 
Electrophoresis was carried out on a Biorad electrophoresis setup and 
electrophoresis power supply system. The chambers of the system were filled 
with 1x TAE buffer (pH 8.0). The PCR products were analyzed on 2% agarose 
gel (1gm agarose, 1ml TAE (50X), and 49 ml distilled water) containing (2 µl of 
10 mg/ml) ethidium bromide. 5.6 µl of the PCR product was mixed with 1.4 µl 
(10x Orange G) and the mixture was loaded on the gel along with 50 bp DNA 
ladder which is used for determining the size of the PCR product, then the gel 
was run on 80 volts for one hour. By using a UV transillomiator and Canon 
digital camera the results of the migration were detected and documented. The 
PCR product (168 bp) migrated just near the 150 bp ladder band. The PCR 
products (168 bp) were cut with SmaI which cleaves the ccc/ggg sequence, 
Figures 3.1 and 3.2. 
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The restriction enzyme digestion of the PCR product for (CYP2C19*2) was 
performed as follows: in a total of 25 µl volume, 10 µl PCR-amplified DNA were 
mixed with 0.5 µl SmaI (20 u/µl), 2.5 µl 10x enzyme buffer, and 12µl nuclease 
free water, the reaction was incubated at 25 oC overnight, then the products 
were analyzed by a 3% agarose gel electrophoreses, two fragments (118 bp 








Figure 3.1. CYP2C19*2 product (168 bp) and SmaI recognition site underlined 
with red color. 
 
  
Figure 3.2. The Recognition Site of Smal restriction enzyme. 
 
 
3.3.2.2. CYP2C19*3 PCR-RFLP procedure 
The PCR mix was amplified as follows: pre-heating (40 oC, 2 min), and initial 
denaturation (95 oC, 3.0 min) were followed by 35 cycles of denaturation (95 oC, 
1 min, annealing (54 oC, 1.0 min, and extension (72 oC, 1.5 min) followed by a 





Electrophoresis, detection and documentation of the PCR products were the 
same as described for CYP2C19*2. The products (271 bp) were cut with BamHI 
which cleaves the GGATCC sequence Figures 3.3 and 3.4. 
 
The restriction enzyme digestion of the PCR product for (CYP2C19*3) has been 
performed as follows: in a total of 25 µl volume, 10 µl PCR-amplified DNA were 
mixed with 1.5 µl BamHl (20 u/µl), 2.5 µl 10x enzyme buffer, and 11 µl nuclease 
free water. The reaction was incubated at 37°C overnight, then the products 
were analyzed by a 3% agarose gel electrophoresis. Figure 3.3 shows the 
sequence, recognition site of BamHI and the location of the primers used to 
amplify the CYP2C19*3 fragment. Figure 3.4 shows the recognition site for 
BamHl restriction enzyme. Two fragments (175 bp and 96 bp) are produced 








Figure 3.3. CYP2C19*3 product (271 bp) and BamHI recognition site 
underlined with red color.   
 
 







Homozygotes for the mutant allele are predicted to have the poor metabolizer 
(PM) phenotype. In all other cases the subjects were assumed to have a normal 
metabolizing activity. 
 
3.4. Statistical analysis 
The statistical packages for the Social Sciences (SPSS) version 2, and the 































4.1. Patients data analysis 
The total number of subjects enrolled in this study was 200. One hundred and 
six of them were females, and 94 were males. 
 
 
4.2. PCR-RFLP CYP2C19 results  
After DNA extraction from blood samples, DNA was run on 1% agarose gel for 
quality and integrity determinations (Figure 4.1). The extracted DNA was 
subjected to two different amplifications:  
 
Firstly using allele specific primers (Table 3.3) for exon 5 we carried out PCR, 
the amplified product which was expected to be 168 bp (Figure 4.2), was then 
subjected to RFLP analysis using SmaI to detect CYP2C19*2 alleles (Figure 
4.3). The CYP2C19*2 mutation deletes a SmaI restriction site in exon 5 which 
results in the inhibition of digestion of the 168 bp PCR product, while normal 
subjects for this allele show digestion with SmaI to give 118 and 50 bp 
fragments. 
 
Second using also allele specific primers (Table 3.3) for exon 4 we carried out 
PCR, the amplified product which was expected to be 271 bp (Figure 4.4) was 
then subjected to RFLP analysis using BamHI to detect CYP2C19*3 alleles 
(Figure 4.5). The CYP2C19*3 mutation deletes a BamHI restriction site in exon 
4 which results in the inhibition of digestion of the 271 bp PCR product, while 





















Figure 4.1. A photograph of DNA extracted from  EDTA - blood samples run on 
1% ethidium bromide stained agarose gel and visualized by UV. Lane M: PCR 
marker, lanes 1-5: samples of extracted DNA 
 
Figure 4.2. Amplification products of CYP2C19*2 by PCR. Amplified products 
of each reaction were analyzed by electrophoresis on 2 % ethidium bromide     
stained agarose gel. Lane M: PCR marker, lane 1: Negative control, lanes 2 





Figure 4.3. Restriction products for CYP2C19*2 by SmaI. Restricted products 
were analyzed by electrophoresis on 3% ethidium bromide stained agarose gel. 
Lane M:  PCR marker, lanes 1 and 2: Heterozygotes, lanes 3 and 4: Normal 
Homozygotes, lane 5: CYP2C19*2 homozygote. 
 
Figure 4.4. Amplification products of CYP2C19*3 by PCR. Amplified products 
of each reaction were analyzed by electrophoresis on 2 % ethidium bromide     
stained agarose gel. Lane M: PCR marker, lane 1: Negative control, lanes 2 






Figure 4.5. Restriction products for CYP2C19*3 by BamHI. Restricted products 
were analyzed on 3% ethidium bromide stained agarose gel. Lane M: PCR 
marker, lanes 1 and 2: Heterozygote samples, lanes 3 and 4: Normal 





4.3. Genotyping analysis 
 
The genotyping (PCR-RFLP) analysis of patients DNA samples showed the 
following results: 3 individuals (1.5%) carried two mutated alleles 
(CYP2C19*2/*2) being homozygous for CYP2C19*2, thus could be classified as 
poor metabolizers, while 13 subjects (6.5%) carried one mutated allele 
(CYP2C19*1/*2) being heterozygous for CYP2C19*2.  
One individual (0.5%) carried two mutated alleles (CYP2C19*3/*3) being 
homozygous for CYP2C19*3, thus could be classified as a poor metabolizer, 










































































Table 4.1. Genotype frequencies of CYP2C19 among the study subjects 
(n=200). 
Genotype n Observed Frequency (%) 
CYP2C19*1/*1 173 86.5 
CYP2C19*1/*2 13 6.5 
CYP2C19*1/*3 6 3.0 
CYP2C19*2/*2 3 1.5 
CYP2C19*2/*3 4 2.0 
CYP2C19*3/*3 1 0.5 
Total 200 100 
 
 
4.4. Allele frequencies 
Based on our genotype frequencies, allele frequencies will be as follows: 91.3% 
wild-type (CYP2C19*1), 5.8% CYP2C19*2, and 3.0% CYP2C19*3 (Table 4.2). 
The derived allele frequency for CYP2C19*2 (5.75%) in this study was 
calculated as follows:  
 
The total number of the CYP2C19*2 alleles                    23                  23 
--------------------------------------------------      x 100%  =   ----------   =    -----------   = 5.8%  
The total number of the CYP2C19 alleles                    200 x 2             400      
 
The total number of the CYP2C19*2 alleles (23) was computed by adding the 
number of alleles present in the heterozygotes (17) to the number of alleles 
present in the homozygotes (2x3=6).  
 




























CYP2C19*1 365 91.3 
CYP2C19*2 23 5.8 
CYP2C19*3 12 3.0 






Throughout history, the Greeks, Romans, Arabs, Turks, French and British have 
all ruled Gaza Strip and mixed with its people, such that modern Gaza Strip now 
is a mixture of all these legacies [60]. Because of the clear heterogeneity and 
genetic admixture in the Gaza Strip population, we considered it especially 
important to investigate the CYP2C19 allelic variants.  
 
The human CYP2Cs are an important subfamily of Cytochrome P450 enzymes 
which metabolize approximately 20% of clinically used drugs and are always 
found to participate in the metabolism of carcinogens or procarcinogens. Some 
are involved in the activation of procarcinogens, some may take part in the 
inactivation of carcinogens. That depends on what kind of carcinogens and 
what kind of cancers, and what kind of mechanism of carcinogenesis [73].  
 
Among these, the CYP2C9 is the most abundant isoform which represents 
approximately 18% of total hepatic CYPs. CYP2C19 is one of the most 
important cytochrome P450s, representing about 3% of total hepatic CYPs [74]. 
CYP2C19 is known as a key enzyme in the in vivo metabolism of a number of 
related hydantoins and barbiturates, as well as in the metabolism of structurally 
unrelated drugs such as omeprazole, lansoprazole, progunil, mephenytoin and 
citalopram [39]. 
 
Several reports of CYP2C genetic polymorphism demonstrate it's potential 
clinical role in determining both inter-individual and inter-ethnic differences in 
drug efficacy. In this study we investigated the distribution of CYP2C19 
common variants in the Gaza Strip population and compared these with those 
from other populations. 
 
CYP2C19 genotyping was conducted on 1356 Caucasian individuals 
throughout the world [60], and it was found that the CYP2C19*2 is the most 
common variant among this ethnic group [75].  
 
Individuals can be divided into two groups, poor metabolizers (PMs) and 
extensive metabolizers (EMs), depending on the hydroxylation ability of S-
mephenytoin. There two main enzyme deficient alleles leading to PM phenotype 
are called CYP2C19*2 (CYP2C19m1) and CYP2C19*3 (CYP2C19m2). The PM 
frequency ranges from 2 to 7% in Caucasians, 1425% in Asians, and 60% in 
the Vanuatu island [76, 78].  
 
An individual who inherits two mutant CYP2C19 alleles, whether of the same 
kind (*2/*2, *3/*3) or different kinds (*2/*3), has a reduced capacity to 
metabolize CYP2C19 substrates and is a PM. Individuals who are homozygous 
(*1/*1) or heterozygous (*1/*2, *1/*3) for wild-type CYP2C19*1 have efficient 
enzyme to metabolize CYP2C19 substrates and are EMs [66].  
 
It has been shown that a higher concentration of omeprazole in PMs results in 
great gastric acid suppression as compared with extensive metabolizers (EMs) 
[87]. Cure rates for H. pylori in patients receiving omeprazole and amoxicillin 
were found to be 28% in homozygous EMs (CYP2C19*1/*1), 60% in 
heterozygous EMs (CYP2C19*1/*2 and *1/*3), and 100% in PMs 
(CYP2C19*2/*2 and *2/*3), indicating the importance of dose adjustment in the 
case of EMs [89]. 
 
In the present study, we found that the allele frequency of CYP2C19*2 in Gaza 
Strip population (6%) was most similar  to Caucasian populations, but it was 
less than that found in other Caucasian populations (11 to 16 %) residing in 
America [79], Canada [80], Europe [80, 81, 82], Australia [83] and Saudi 
Arabia [60]. Higher frequencies of CYP2C19*2 were reported for Asian 
populations (20-39%) [60,4,72], North Indians (30%) [84], Africans (13 21%) 
[85,86,87] and African Americans (25%) [60] (Table 5.1). 
 
The allele frequency of CYP2C19*1 recorded in this study (91%) is significantly 
higher in Gaza Strip when compared with that of other populations.  
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Table 5.1. Distribution of CYP2C19 variant alleles among different ethnic 
groups.  
Allele frequency (%) Ethnicity 
WT (*1) m1 (*2) m2 (*3) 
Reference 
Non-Asians 
Palestinian (Gaza Strip) 91.3 5.8 3 Present study 
Egyptian 88.8 11 0.2 [58] 
Israeli Jewish 84 15 1 [59] 
Caucasians 
Iranian 86 14 0 [77] 
Saudi Arabian 85 15 0 [60] 
Australian 85 15 0 [83] 
Canadian (Inuit) 89 11 0 [79] 
Swedish 84.9 14.4 0.7 [88] 
Danish 84 16 0 [80] 
European American 87 13 0 [4,60] 
Asians 
Sum for Asians 62 32 6 [4,60] 
Chinese-Taiwanese 63 32 5 [60] 
Japanese 67 23 10 [4,60] 
Filipinos 54 39 7 [4,60] 
Korean 67 21 12 [85] 
South-west Asia 
North Indian 70 30 0 [84] 
Africans 
African American 75 25 0 [4,60] 
Bantu-Tanzanian 81.5 18 0.5 [85] 
Ethiopian 85 13 2 [86] 
Venda 78 22 0 [87] 
Zimbabwean 87 13 0 [87] 
 
On the other hand, the discovered presence of CYP2C19*3 in one Gaza Strip 
subject (3%) was an interesting finding because limited numbers of studies 
have reported CYP2C19*3 in populations other than the Asians. CYP2C19*3 
was reported in the Swedish population (3%) [88], (7%) [89], the Bantu-
Tanzanians (6%) [85] and the Ethiopians (18%) [86]. The CYP2C19*3 has 
been regarded as an Asian mutation. A possible explanation for our finding of 
CYP2C19*3 in the Gaza Strip population may be the emigration and possible 
genetic admixture between the Gaza Strip population and Asian population.  
 
By comparing our results with our neighbor the Egyptian population, we found 
that the incidence of CYP2C19*2 in Egyptians (11%) was similar to that found in 
other Caucasian populations (1116%), but the incidence of this allele in Gaza 
strip population is lower than them (5.8%), they also reported only a (0.2%) 
incidence of CYP2C19*3 as compared to our finding of (3%) [58]. 
 
When comparing our result with the Israeli Jewish population, their CYP2C19*2 
incidence of (15%) was higher than our allele incidence (5.8%) but similar to 
that found in other Caucasian populations (1116%). For CYP2C19*3, the 
reported incidence of (1%) is lower than our reported value (3%). They 
concluded that the CYP2C19 allele frequencies of  Israeli Jewish population 
resemble those of the non-Asian populations [59]. 
 
The incidence of CYP2C19*2 in Saudi Arabians (15%) was similar to that found 
in European-Americans, and significantly lower than that found in Asian 
populations or African-Americans. Moreover CYP2C19*3 was not found in 
Saudi Arabians. The Saudi Arabians results were similar to those found in other 
Caucasian populations, but different from our findings as we reported the 




In future drug treatment genotyping will probably be very important for 
prediction of drug efficacy and drug toxicity. So predictive genotyping might 
prevent serious or fatal adverse drug reactions. 
 
In conclusion, the tested allelic variants of CYP2C19 existed in Gaza Strip 
people with frequencies comparable to other Caucasian populations have some 
differences from those of  Asians and African Americans. Because these 
genetic polymorphisms are medically significant, clinicians may use genotyping 
for optimization of therapy or identification of persons at risk of adverse drug 
reactions before clinical trials, as pharmacogenetics have many potential 
benefits: 
 
 Improving drug safety. If a specific genotypic variant is found to be 
associated with an adverse reaction, physicians could avoid prescribing 
the medicine to patients with this genotype.  
 
 Adjusting dosage. Knowledge of genotypes with specific 
pharmacokinetic characteristics could be used to adjust the dosage of 
affected drugs, reducing the trial-and-error approach of pre-scribers to 
determine the most effective dose. 
 
 Enhancing efficacy. Many widely used treatments for major diseases, 
such as diabetes, depression, and asthma, are effective in only half the 
population. Rather than using trial and error with all its attendant 
problems, pharmacogenetics may identify responsive and non-
responsive patients or offer new medicines designed on the basis of the 





It is hoped that our results will aid in understanding the ethnic diversity of the 
Gaza Strip population, and offer a preliminary basis for more rational use of 
















Conclusions and Recommendation 
 
The present study focuses on the polymorphism of CYP2C19 gene in 200 
unrelated healthy Palestinian subjects residing in Gaza Strip. 
  
The results of the study can be summarized as follows: 
 
 Allele frequency: 91.3% for CYP2C19*1, 5.8% for CYP2C19*2, and 
3.0% for CYP2C19*3. 
 
 Genotype frequency: 86.5% for CYP2C19*1/*1, 6.5% for 
CYP2C19*1/*2, 3% for CYP2C19*1/*3, 1.5% for CYP2C19*2/*2, 2% for 
CYP2C19*2/*3, and 0.5% for CYP2C19*3/*3. 
 
 The CYP2C19*1 is significantly higher in Gaza Strip when compared with 
other populations.  
 
 The distribution of CYP2C19*2 in the Gaza Strip population is lower than 
that in Caucasians, Africans or  Asian populations.  
 
 The CYP2C19*3 allele, which was not reported in the Caucasian 




We recommend that further studies should be conducted in order to 
investigate and establish the relation between CYP2C19 polymorphism and 
response to chemotherapeutic drugs, severity of certain diseases, and the 
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